Dental Practice Broker: The Incentive Problem Nobody Explains

There is a sentence every dental practice owner should read before they sign a listing agreement, and almost no broker will say it out loud:

Your broker gets paid whether you net $4.2 million or $3.1 million.

That is not an accusation. It is the structure. And here is the part that may surprise you, coming from a forensic firm: you should almost certainly use a broker. In an institutional or private-equity process, representation is not optional. Even in a doctor-to-doctor sale, you want an advisor or advocate who has walked the path before. The question is never whether to have a broker. It is what to expect from one — and what they were never built to do.

Let me be fair before I am critical: a good broker does real, valuable work you should not attempt alone. Then let me show you the one gap the broker model was never built to fill — and why that gap is where founders quietly lose the most money.

What a dental practice broker actually does well

A broker is a distribution engine. Engaged properly, they do several things you genuinely should not do alone:

They build the Confidential Information Memorandum — the marketing document that presents your practice to buyers. They run buyer outreach, tapping a network of DSOs, private-equity platforms, and individual acquirers you would never reach on your own. They manufacture competitive tension — the single most valuable thing a broker can do, because a real or perceived competing bid is what holds a number up. And they absorb the emotional load of negotiation, sitting between you and a buyer so you do not torch the deal in a moment of frustration.

In my world — institutional and PE transactions — going to the table without that representation is not brave, it is reckless. In a doctor-to-doctor deal, a broker or advisor who knows the process pays for themselves in the terms they protect. If you have never run a sale process, attempting to self-broker your exit is false economy.

So this is not a “brokers are bad” article. It is a “know what you are buying” article. Because the way brokers are paid creates a blind spot that has nothing to do with their character and everything to do with their incentives.

The success-fee model, and what it quietly optimizes for

Most sell-side brokers in the lower-middle market work on a success fee — an all-in commission of roughly 6% to 12% of final deal value, payable only when the deal closes and funds. Many use a Double Lehman scale: 10% of the first million, 8% of the second, 6% of the third, 4% of the fourth, 2% thereafter.

Read that structure carefully, because it tells you exactly what the broker is optimizing for.

First, the fee is front-loaded. The broker captures the richest percentages on the first few million of deal value. The marginal dollars at the top of your valuation — the ones a buyer’s diligence team will fight hardest to strip — are worth the least to your broker. They earn 2% defending your fifth million and 10% closing your first.

Second, the fee is contingent on closing. The broker earns nothing on a deal that falls apart, and a substantial six-figure fee on a deal that closes — at almost any price. A $4M deal re-traded down to $3.1M still pays the broker a large fee. A $4M deal the seller walks away from on principle pays the broker nothing.

Now put yourself in the room at the moment that matters most.

The re-trade — and the moment the incentives diverge

Here is how a typical institutional process unfolds. You engage the broker. They build the memo on your strongest trailing year. They attract interest and create a competitive process. You sign a Letter of Intent at a compelling multiple. The headline number is real, and everyone celebrates.

Then the exclusivity clock starts, and the buyer’s Quality of Earnings team goes to work — extracting five years of raw practice-management data, mapping your CDT utilization against benchmarks, testing every add-back. (I have written the full anatomy of how DSOs evaluate a practice elsewhere.) Around day 50, the QoE draft lands, and it does not look like the broker’s memo. Add-backs reversed. Utilization flagged. The buyer’s sponsor calls and is “disappointed.” The math, they say, has to change.

This is the re-trade. And it is the precise moment your broker’s incentives and yours stop pointing the same direction.

You want to fight — or walk. But you are 60 days into exclusivity, you have told your family you are retiring, and walking means starting a nine-month process over from scratch with the stigma of a broken deal. Your broker, meanwhile, is looking at a large fee that closes if you accept the lower number and evaporates if you walk. The broker’s marginal incentive at the re-trade is not to defend your number to the last dollar. It is to manage your expectations downward so the deal closes.

The broker often pivots — gently, professionally — from your advocate to the deal’s closer. Not out of malice. Out of math.

Why nobody fights it: the comfort of a survivable loss

Here is the uncomfortable truth about why this pattern has persisted for decades, largely unchallenged: the haircut is survivable.

The seller who expected $4.2M and nets $3.5M did not go from wealthy to broke. They still retire. They still travel with their spouse. They still pay off the house and set up the grandkids. The number that landed is less than they deserved — but it is not a catastrophe. And that, precisely, is why the pain gets absorbed instead of avoided.

A loss that ruins you gets talked about. A loss that merely shrinks an already-comfortable retirement gets rationalized — “that’s just how these deals go.” The seller tells their peers the headline number, not the wire. The broker moves to the next listing. The next founder walks in believing the same story, because no one in the process has any incentive to call the haircut what it actually is: avoidable.

That is the false sense of security, and it is structural. The re-trade does not feel like a wound because the cushion is thick enough to hide it. So an entire profession has quietly accepted six- and seven-figure value erosion as a cost of doing business — a tax, rather than a leak.

We are, right now, one of the only voices saying out loud that it is a leak. And the burn is real — it intensifies the moment you can see it coming, because once you understand the mechanism, you cannot un-see that the $700,000 you left on the table was defensible. Most dentists walk into the wood chipper first and read an article like this second. The entire point of starting years early is to read it first.

The gap the broker model was never built to fill

Notice what is missing from everything a broker does. They market your number. They do not defend it.

A broker will tell you to “get your financials clean” before you go to market. What they will not do — because it is a different discipline, a different cost structure, and outside their success-fee incentive — is run the buyer’s forensic audit on you, first. They do not extract your raw PMS data and cross-reference your ledgers against your treatment planner. They do not benchmark your provider-level CDT utilization the way a Cotiviti-style audit will. They do not build the documented, dated evidence trail that turns “unexplained variance” into “remediated and corroborated.”

That is the Defense Gap: the buyer arrives with a six-figure forensic team, and the seller arrives with a broker paid to close. The broker is not equipped to fight a QoE re-trade, and is not paid to. So the variance the buyer finds becomes a discount — and the discount becomes the broker’s “let’s just get it done.”

This is why the most important work in a dental practice sale happens before the broker ever takes you to market — and often years before. You harden the data. You substantiate the add-backs as they occur. You run your own Quality of Earnings audit and remediate what it finds while you still control the narrative. Then, when the broker creates competitive tension and the buyer’s QoE team goes looking for leverage, there is nothing left to extract — and your broker’s “manage expectations down” conversation never has to happen.

So — do you need a broker?

Yes. In an institutional process, without question — and in a doctor-to-doctor deal, at minimum an advisor or advocate who has run the process before. Do not read any of this as “skip the broker.” Read it as: use them for what they are — a channel and a process manager — and do not hand them the one job they were never built or paid to do, which is defending your number through the audit.

The owners who keep their full value treat the two as separate jobs. They engage a broker to run the market. And they engage a forensic discipline — in-house or advisory — to build a number that survives the QoE. Done right, the two reinforce each other: a clean, pre-audited practice is easier for your broker to sell and harder for a buyer to re-trade. Your forensic preparation does not compete with your broker — it makes them look good.

Before you interview a single broker, find out where your number actually stands against the audit a buyer will run. Run the valuation calculator to see your range, and read Phantom EBITDA to understand exactly what a QoE team disallows. Then bring a broker in to do what brokers do well — sell a number you have already made defensible.

A broker sells the story. You are responsible for making sure the story survives the audit — and for refusing to accept a survivable loss as an inevitable one. Know the difference before you sign.